Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

In the short term, the U.S. government must move urgently to shore up supply-chain vulnerabilities in critical drug categories - starting with antibiotics. Amoxicillin, a drug that is hard to find in ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing.